A new staging system for cardiac transthyretin amyloidosis.
Eur Heart J. 2018 Aug 7;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589.
Eur Heart J. 2018.
PMID: 29048471
Stage I was defined as NT-proBNP 3000 ng/L and eGFR 45 ml/min, Stage III was defined as NT-proBNP >3000 ng/L and eGFR <45 ml/min, and the remainder were Stage II. ...Median survival among 393 (45%) Stage I patients was 69.2 months, …
Stage I was defined as NT-proBNP 3000 ng/L and eGFR 45 ml/min, Stage III was defined as NT-proBNP >3000 ng/L …